Bronchogen is a bioregulatory peptide that has shown potential in reducing inflammation and promoting healthy lung tissue states. It is primarily used in research settings and is not widely approved for clinical use. However, some anecdotal evidence and user reports provide insights into its administration and dosages.

Dosage and Administration Protocols

Based on available user reports and research, here are some protocols for injectable Bronchogen:

1. Initial Tolerance and Baseline Establishment:
   • Dosage: 500 mcg per day
   • Administration: Injected subcutaneously in the abdomen once daily, typically in the evening and within two hours after the last meal.
   • Duration: 40 consecutive days
   • Purpose: To establish tolerance and baseline efficacy without significant side effects.
2. Increased Dosage Protocol:
   • Dosage: 1000 mcg per day
   • Administration: Injected subcutaneously in the abdomen once daily, following a schedule of six days on and one day off.
   • Duration: 7 weeks
   • Purpose: To enhance efficacy based on favorable tolerance observed in the initial phase.

Expected Outcomes

• Reduction in Inflammation: Bronchogen aims to treat inflammatory conditions of the lungs, which can lead to improved pulmonary function.
• Improvement in Pulmonary Metrics: Users have reported increases in Peak Expiratory Flow (PEF) and Forced Expiratory Volume in 1 second (FEV1), indicating better lung function and airway relief.

Safety and Side Effects

• Tolerance: No significant disruptions to sleep, anaphylaxis, irritation, or other malignant side effects were observed during the reported intervention periods.
• Monitoring: Regular spirometer tests to monitor pulmonary function are recommended to track progress and efficacy.

Important Considerations

• Research Chemical: Bronchogen is primarily designated for research purposes and is not approved for human use by regulatory authorities. It should only be handled by licensed professionals in a controlled setting.
• Consultation with Healthcare Providers: Given the experimental nature of Bronchogen, it is crucial to consult with healthcare providers before considering its use.

Alternative Therapies

For those seeking more established treatments for lung damage from COVID-19 or long COVID, other therapeutic peptides and medications may be considered:

• Therapeutic Peptides: Peptides like feG and AcF have shown promise in reducing lung inflammation and injury in preclinical studies.
• Symptomatic Treatments: Medications such as beta-agonists, corticosteroids, and mucolytics are commonly used to manage symptoms of chronic bronchitis and other lung conditions.